Psychedelics
PharmaTher Expecting FDA Approval for Ketamine Treatment in April
Toronto-based PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is expecting to get full approval from the U.S. Food and Drug Administration (FDA) …
Toronto-based PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is expecting to get full approval from the U.S. Food and Drug Administration (FDA) in April for a ketamine-based treatment it’s developed to be used for a wide array of “pain, mental health, and neurological disorders,” the company announced Wednesday.
PharmaTher had submitted an application to the FDA last year for its ketamine-based drug KETARX, which it had indicated at the time could be used to combat Parkinson’s Disease. The company said it learned in September that the FDA set an “approval goal date” of April 29, 2024, and reported this week that it had confirmed that the date is “still on track.”
If KETARX gets the thumbs up from the FDA, PharmaTher said it intends to restart a wider range of treatment products and regimens that target far more ailments than just Parkinson’s Disease. Rather, the company said in a press release that its “long-term strategy is pursuing novel uses and delivery methods of ketamine as a potential treatment for pain, mental health, and neurological disorders.”
That includes backfilling a national ketamine shortage, applying for government approvals in other countries for KETARX, and ongoing product research and development, PharmaTher indicated.
PharmaTher is confident enough that it’s getting the green light from the FDA that it said it’s proceeding with the reallocation of company funds for “the U.S. commercial scale-up and international regulatory approvals,” while it hits “pause” on spending for “product and clinical programs.”
Those programs – including treatments for Parkinson’s disease, Amyotrophic Lateral Sclerosis, Rett Syndrome, and Complex Regional Pain Syndrome – may be restarted in the second half of the year if PharmaTher can find the right partners with whom to run them.
“We believe 2024 will be a transformative year for PharmaTher with the expected FDA approval of ketamine,” PharmaTher CEO Fabio Chianelli said in a release.
Following the approval, KETARX will be manufactured in the U.S. at a federally certified facility, and then PharmaTher will turn to Canada, where there’s also been a ketamine shortage since February 2023.
Ketamine is used in Canada as a sedative and painkiller, as opposed to solely for specific ailments such as Parkinson’s Disease, PharmaTher noted. It’s also “administered in hospitals and clinics to treat various mental health, neurological and pain disorders,” the company said in its release, and cited a recent study that found positive results from ketamine in patients dealing with “depression, anxiety, and suicidal ideation.”
The post PharmaTher Expecting FDA Approval for Ketamine Treatment in April appeared first on Green Market Report.
ketamine depression anxiety cse fda research-
Psilocybin7 days ago
The Psychedelic Scene in Oaxaca, Mexico
-
Law & Regulation1 week ago
GH Research advances depression therapies, burns cash
-
Psychedelics1 week ago
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
-
Law & Regulation4 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics5 days ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
-
Psychedelics5 days ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics6 days ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance